Hillevax Inc

Hillevax Inc (HLVX) Stock Analysis

$2.090

-0.010 (-0.48%)At close

Loading chart…
High
2.110
Open
2.100
VWAP
2.10
Vol
2.80M
Mkt Cap
664.77M
Low
2.090
Amount
5.87M
EV/EBITDA, TTM
0.76

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The Company has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

www.hillevax.com

Valuation Metrics

The current forward P/E ratio for Hillevax Inc (HLVX) is -0.87, compared to its 5-year average forward P/E of -3.34.

Forward P/E

Overvalued
5Y Average P/E
-3.34
Current P/E
-0.87
Overvalued
-1.69
Undervalued
-4.98

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
-1.57
Current EV/EBITDA
0.76
Overvalued
0.09
Undervalued
-3.23

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for HLVX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HLVX

$2.37

Scenario price

B

Base

Base · 50%HLVX

$2.23

Scenario price

B

Bear

Bear · 25%HLVX

$2.17

Scenario price

Events Timeline

2025-09-17 (ET)

09:06:15

Xoma Completes Tender Offer for HilleVax

2025-08-04 (ET)

07:04:21

HilleVax to be acquired by XOMA Royalty for $1.95 in cash per share plus CVR

2025-05-08 (ET)

07:26:04

HilleVax reports Q1 EPS (12c) vs (97c) last year

2024-11-07 (ET)

07:08:17

HilleVax reports Q3 EPS (52c), consensus (42c)

Show More Events

News

Show More News

HLVX FAQ — answered by Alphio AI

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The Company has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started